AU779697B2 - Method for producing an injectable medicament preparation - Google Patents

Method for producing an injectable medicament preparation Download PDF

Info

Publication number
AU779697B2
AU779697B2 AU59709/00A AU5970900A AU779697B2 AU 779697 B2 AU779697 B2 AU 779697B2 AU 59709/00 A AU59709/00 A AU 59709/00A AU 5970900 A AU5970900 A AU 5970900A AU 779697 B2 AU779697 B2 AU 779697B2
Authority
AU
Australia
Prior art keywords
protein
active compound
spacer
group
agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
AU59709/00A
Other languages
English (en)
Other versions
AU5970900A (en
Inventor
Felix Kratz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
KTB Tumorforschungs GmbH
Original Assignee
KTB Tumorforschungs GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=7910588&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU779697(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by KTB Tumorforschungs GmbH filed Critical KTB Tumorforschungs GmbH
Publication of AU5970900A publication Critical patent/AU5970900A/en
Application granted granted Critical
Publication of AU779697B2 publication Critical patent/AU779697B2/en
Anticipated expiration legal-status Critical
Expired legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Virology (AREA)
  • Rheumatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AU59709/00A 1999-06-09 2000-06-07 Method for producing an injectable medicament preparation Expired AU779697B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE19926154A DE19926154A1 (de) 1999-06-09 1999-06-09 Verfahren zur Herstellung einer injizierbaren Arzneimittelzubereitung
DE19926154 1999-06-09
PCT/EP2000/005272 WO2000076551A2 (de) 1999-06-09 2000-06-07 Verfahren zur herstellung einer injizierbaren arzneimittelzubereitung

Publications (2)

Publication Number Publication Date
AU5970900A AU5970900A (en) 2001-01-02
AU779697B2 true AU779697B2 (en) 2005-02-10

Family

ID=7910588

Family Applications (1)

Application Number Title Priority Date Filing Date
AU59709/00A Expired AU779697B2 (en) 1999-06-09 2000-06-07 Method for producing an injectable medicament preparation

Country Status (13)

Country Link
US (5) US7387771B1 (enExample)
EP (3) EP1183050B1 (enExample)
JP (5) JP5517384B2 (enExample)
AT (1) ATE339225T1 (enExample)
AU (1) AU779697B2 (enExample)
CA (1) CA2374964C (enExample)
CY (2) CY1105701T1 (enExample)
DE (2) DE19926154A1 (enExample)
DK (3) DK2347770T4 (enExample)
ES (3) ES2623017T5 (enExample)
PT (3) PT2347770T (enExample)
SI (1) SI1704864T1 (enExample)
WO (1) WO2000076551A2 (enExample)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7601691B2 (en) 1999-05-17 2009-10-13 Conjuchem Biotechnologies Inc. Anti-obesity agents
US6514500B1 (en) 1999-10-15 2003-02-04 Conjuchem, Inc. Long lasting synthetic glucagon like peptide {GLP-!}
US6887470B1 (en) 1999-09-10 2005-05-03 Conjuchem, Inc. Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
WO2000069902A1 (en) 1999-05-17 2000-11-23 Conjuchem, Inc. Long lasting fusion peptide inhibitors or viral infection
US7144854B1 (en) 1999-09-10 2006-12-05 Conjuchem, Inc. Long lasting anti-angiogenic peptides
DE60006100T2 (de) 1999-05-17 2004-07-01 Conjuchem, Inc., Montreal Lang wirkende insulinotrope peptide
US6849714B1 (en) 1999-05-17 2005-02-01 Conjuchem, Inc. Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
DE19926154A1 (de) * 1999-06-09 2000-12-14 Ktb Tumorforschungs Gmbh Verfahren zur Herstellung einer injizierbaren Arzneimittelzubereitung
DE19926475A1 (de) * 1999-06-10 2000-12-14 Ktb Tumorforschungs Gmbh Träger-Pharmaka-Konjugate
US6706892B1 (en) 1999-09-07 2004-03-16 Conjuchem, Inc. Pulmonary delivery for bioconjugation
EP1889639A3 (en) * 1999-09-07 2008-04-09 ConjuChem Biotechnologies Inc. Methods and compositions containing succinimide or maleimide derivatives of antineoplastic agents, for producing long lasting antineoplastic agents
CA2383794A1 (en) * 1999-09-07 2001-03-15 Conjuchem Inc. Methods and compositions containing succinimide or maleimide derivatives of antineoplastic agents
US7090851B1 (en) 1999-09-10 2006-08-15 Conjuchem Inc. Long lasting fusion peptide inhibitors of viral infection
US6961567B1 (en) * 2000-12-07 2005-11-01 Palm, Inc. Generic activation and registration framework for wireless devices
US7555571B1 (en) * 2001-01-05 2009-06-30 Palm, Inc. Activation of mobile computing device on a cellular network
EP1355941A2 (en) 2001-02-02 2003-10-29 ConjuChem, Inc. Long lasting growth hormone releasing factor derivatives
WO2002066511A2 (en) 2001-02-16 2002-08-29 Conjuchem Inc. Long lasting glucagon-like peptide 2 (glp-2) for the treatment of gastrointestinal diseases and disorders
US8812398B2 (en) * 2001-05-08 2014-08-19 Qualcomm Incorporated Key for a wireless-enabled device
DE60229677D1 (de) 2001-05-31 2008-12-11 Conjuchem Biotechnologies Inc Langwirkende Fusionspeptidinhibitoren gegen HIV-Infektion
US8435529B2 (en) 2002-06-14 2013-05-07 Immunomedics, Inc. Combining radioimmunotherapy and antibody-drug conjugates for improved cancer therapy
US8877901B2 (en) 2002-12-13 2014-11-04 Immunomedics, Inc. Camptothecin-binding moiety conjugates
US7591994B2 (en) 2002-12-13 2009-09-22 Immunomedics, Inc. Camptothecin-binding moiety conjugates
US7585491B2 (en) 2002-12-13 2009-09-08 Immunomedics, Inc. Immunoconjugates with an intracellularly-cleavable linkage
US9770517B2 (en) 2002-03-01 2017-09-26 Immunomedics, Inc. Anti-Trop-2 antibody-drug conjugates and uses thereof
DE10310082A1 (de) 2003-03-07 2004-09-16 Ktb Tumorforschungsgesellschaft Mbh Protein-bindende Doxorubicin-Peptid-Derivate
GB0321613D0 (en) * 2003-09-15 2003-10-15 Drug Discovery Lab As Compounds
CA2564031A1 (en) 2004-04-23 2005-11-03 Conjuchem Biotechnologies Inc. Method for the purification of albumin conjugates
DE102005002991A1 (de) * 2005-01-21 2006-07-27 Rösner Research GmbH & Co.KG Verfahren zur Herstellung von Albumin-Konjugaten mit Gyrasehemmern
US10058621B2 (en) 2015-06-25 2018-08-28 Immunomedics, Inc. Combination therapy with anti-HLA-DR antibodies and kinase inhibitors in hematopoietic cancers
US9707302B2 (en) 2013-07-23 2017-07-18 Immunomedics, Inc. Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer
US8039432B2 (en) * 2005-11-09 2011-10-18 Conjuchem, Llc Method of treatment of diabetes and/or obesity with reduced nausea side effect
DE102006024528A1 (de) * 2006-05-23 2007-11-29 Albupharm Heidelberg Gmbh & Co. Kg Neue, an der Tumorphysiologie orientierte Formulierung eines Zytostatikums, insbesondere von cis-Platin
DE102007002726A1 (de) * 2007-01-18 2008-07-31 Bayer Schering Pharma Aktiengesellschaft Neue Kaskaden-Polymer-Komplexe, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Mittel
EP3453405A1 (en) 2007-02-16 2019-03-13 Vergell Medical S.A. Dual acting prodrugs
PT3903829T (pt) 2009-02-13 2023-06-02 Immunomedics Inc Imunoconjugados com uma ligação intracelular clivável
EP2289558A1 (en) * 2009-08-25 2011-03-02 KTB Tumorforschungsgesellschaft mbH Bisphosphonate-prodrugs
EP2359802B1 (en) * 2010-02-12 2014-06-18 Evonik Degussa GmbH Cosmetic composition containing polyglycerol partial ester
EP2382993A1 (en) * 2010-04-19 2011-11-02 KTB Tumorforschungsgesellschaft mbH Combination of drugs with protein-binding prodrugs
US9382329B2 (en) 2012-08-14 2016-07-05 Ibc Pharmaceuticals, Inc. Disease therapy by inducing immune response to Trop-2 expressing cells
US9931417B2 (en) 2012-12-13 2018-04-03 Immunomedics, Inc. Antibody-SN-38 immunoconjugates with a CL2A linker
CN104837508A (zh) 2012-12-13 2015-08-12 免疫医疗公司 功效改进且毒性降低的抗体与sn-38的免疫缀合物的剂量
US12310958B2 (en) 2012-12-13 2025-05-27 Immunomedics, Inc. Antibody-drug conjugates and uses thereof
US10744129B2 (en) 2012-12-13 2020-08-18 Immunomedics, Inc. Therapy of small-cell lung cancer (SCLC) with a topoisomerase-I inhibiting antibody-drug conjugate (ADC) targeting Trop-2
WO2015012904A2 (en) 2012-12-13 2015-01-29 Immunomedics, Inc. Antibody-sn-38 immunoconjugates with a cl2a linker
US20240148873A1 (en) 2012-12-13 2024-05-09 Immunomedics, Inc. Dosages of immunoconjugates of antibodies and sn-38 for improved efficacy and decreased toxicity
US10413539B2 (en) 2012-12-13 2019-09-17 Immunomedics, Inc. Therapy for metastatic urothelial cancer with the antibody-drug conjugate, sacituzumab govitecan (IMMU-132)
AU2013359048A1 (en) 2012-12-13 2015-07-02 Cytrx Corporation Anthracycline formulations
US10206918B2 (en) 2012-12-13 2019-02-19 Immunomedics, Inc. Efficacy of anti-HLA-DR antiboddy drug conjugate IMMU-140 (hL243-CL2A-SN-38) in HLA-DR positive cancers
US9492566B2 (en) 2012-12-13 2016-11-15 Immunomedics, Inc. Antibody-drug conjugates and uses thereof
US10137196B2 (en) 2012-12-13 2018-11-27 Immunomedics, Inc. Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity
BR112015014712A2 (pt) 2012-12-21 2017-07-11 Abgenomics Int Inc ligadores de autoimolação hidrofílicos e seus conjugados
CN105307724A (zh) 2013-06-05 2016-02-03 西特克斯公司 用于治疗癌症的细胞毒素剂
US11253606B2 (en) 2013-07-23 2022-02-22 Immunomedics, Inc. Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, Bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer
AU2015276821A1 (en) 2014-06-20 2017-01-12 Abgenomics International Inc. Anti-folate receptor aplha (FRA) antibody-drug conjugates and methods of using thereof
KR101759261B1 (ko) 2014-11-20 2017-07-19 파로스젠 주식회사 유도형질로 활성화되는 다기능성 항암제 전구체, 이의 제조방법 및 이의 용도
CA2981543A1 (en) 2015-04-22 2016-10-27 Immunomedics, Inc. Isolation, detection, diagnosis and/or characterization of circulating trop-2-positive cancer cells
WO2016205738A2 (en) 2015-06-19 2016-12-22 Cytrx Corporation Delivery systems for controlled drug release
US10195175B2 (en) 2015-06-25 2019-02-05 Immunomedics, Inc. Synergistic effect of anti-Trop-2 antibody-drug conjugate in combination therapy for triple-negative breast cancer when used with microtubule inhibitors or PARP inhibitors
CA3004630A1 (en) 2015-12-09 2017-06-15 Medizinische Universitat Wien Monomaleimide-functionalized platinum compounds for cancer therapy
IL260289B (en) 2016-01-08 2022-08-01 Bioalliance Cv Tetravalent anti-psgl-1 antibodies and uses thereof
CN108601841A (zh) 2016-02-10 2018-09-28 免疫医疗公司 Abcg2抑制剂与sacituzumab govitecan(immu-132)的组合克服表达trop-2的癌中对sn-38的抗性
WO2017147240A1 (en) 2016-02-23 2017-08-31 Tarveda Therapeutics, Inc. Hsp90 targeted conjugates and particles and formulations thereof
CN109310385A (zh) 2016-04-27 2019-02-05 免疫医疗公司 抗trop-2-sn-38抗体药物缀合物用于检查点抑制剂复发/难治的肿瘤的疗法的功效
CA3050332A1 (en) 2017-03-27 2018-10-04 Immunomedics, Inc. Treatment of trop-2 expressing triple negative breast cancer with sacituzumab govitecan and a rad51 inhibitor
WO2018187074A1 (en) 2017-04-03 2018-10-11 Immunomedics, Inc. Subcutaneous administration of antibody-drug conjugates for cancer therapy
CA3073045A1 (en) 2017-08-15 2019-02-21 Nantcell, Inc. Hank cetuximab combinations and methods
JP2021014409A (ja) * 2017-11-21 2021-02-12 京都薬品工業株式会社 タンパク質結合性薬物
US11572373B2 (en) * 2017-11-30 2023-02-07 Ladrx Corporation Maytansinoid-based drug delivery systems
NZ764948A (en) 2017-11-30 2024-08-30 Ladrx Corp Albumin-binding prodrugs of auristatin e derivatives
WO2020081174A1 (en) 2018-10-16 2020-04-23 Nant Holdings Ip, Llc Alpha emitter compositions and methods

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4251445A (en) 1978-03-24 1981-02-17 Weltman Joel K N-succinimidyl haloacetyl aminobenzoates as coupling agents
EP0024464B1 (en) 1979-08-29 1982-05-12 Nihon Medi-Physics Co., Ltd. 2-oxopropionaldehyde bis(thiosemicarbazone)derivatives and their production and use
US4894226A (en) * 1986-11-14 1990-01-16 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polyproline conjugation
US5612034A (en) 1990-10-03 1997-03-18 Redcell, Inc. Super-globuling for in vivo extended lifetimes
US5827819A (en) * 1990-11-01 1998-10-27 Oregon Health Sciences University Covalent polar lipid conjugates with neurologically active compounds for targeting
EP0493745A1 (en) * 1990-12-21 1992-07-08 Dojindo Laboratories Fluorescent compound, complex, reagent, and specific binding assay employing said reagent
DE4122210C2 (de) 1991-07-04 1999-04-01 Deutsches Krebsforsch Konjugate aus tumoraktiver Verbindung und Serumalbumin sowie Verfahren zu deren Herstellung und ihre Verwendung
US5622929A (en) 1992-01-23 1997-04-22 Bristol-Myers Squibb Company Thioether conjugates
PL319100A1 (en) 1994-09-13 1997-07-21 Theratech Intracellular delivery of chemical agents to cells of specific type
IT1282625B1 (it) * 1996-02-14 1998-03-31 Zambon Spa Composizione farmaceutica atta ad inibire la formazione di metastasi tumorali
US5840733A (en) * 1996-07-01 1998-11-24 Redcell, Canada, Inc. Methods and compositions for producing novel conjugates of thrombin inhibitors and endogenous carriers resulting in anti-thrombins with extended lifetimes
DE19636889A1 (de) † 1996-09-11 1998-03-12 Felix Dr Kratz Antineoplastisch wirkende Transferrin- und Albuminkonjugate zytostatischer Verbindungen aus der Gruppe der Anthrazykline, Alkylantien, Antimetabolite und Cisplatin-Analoga und diese enthaltende Arzneimittel
US5879897A (en) 1996-09-23 1999-03-09 Wake Forest University Methods and compositions for the diagnosis of extraesophageal gastric reflux
EP0966304B1 (en) * 1997-02-20 2005-05-25 David S. Dime Site-specific drug delivery
JP4236812B2 (ja) 1997-09-12 2009-03-11 エクシコン エ／エス オリゴヌクレオチド類似体
IL133053A0 (en) * 1998-03-23 2001-03-19 Conjuchem Inc Local delivery of long lasting therapeutic agents
DE19923168A1 (de) 1999-05-20 2000-11-23 Roche Diagnostics Gmbh Neue Fluoreszenzfarbstoffe und ihre Verwendung als Fluoreszenzmarker
DE19926154A1 (de) * 1999-06-09 2000-12-14 Ktb Tumorforschungs Gmbh Verfahren zur Herstellung einer injizierbaren Arzneimittelzubereitung
DE19926475A1 (de) * 1999-06-10 2000-12-14 Ktb Tumorforschungs Gmbh Träger-Pharmaka-Konjugate
US20060233701A1 (en) 2005-03-30 2006-10-19 Thomas Parias Method and apparatus to improve the industrial production of hydrogen-carbon monoxide

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
KRATZ ET AL BIOL. PHARM. BULL 21(1) (1998) PP 56-61 *
KRUGER ET AL CHEM. PHARM. BULL 45(2) (1997) PP 399-401 *
NICHIFOR ET AL J. CONTROLLED RELEASE 39 (1996) PP 79-92 *

Also Published As

Publication number Publication date
PT2347770T (pt) 2017-06-20
JP5517384B2 (ja) 2014-06-11
EP2347770A3 (de) 2011-11-09
US20150196573A1 (en) 2015-07-16
US20100215574A1 (en) 2010-08-26
DK2347770T3 (en) 2017-07-03
ES2269160T3 (es) 2007-04-01
JP2014055192A (ja) 2014-03-27
EP1704864A3 (de) 2007-01-10
US20060233707A1 (en) 2006-10-19
WO2000076551A3 (de) 2001-08-16
EP1704864B9 (de) 2012-09-19
EP1704864B1 (de) 2012-05-23
EP1183050A2 (de) 2002-03-06
US20120195832A1 (en) 2012-08-02
JP2016047847A (ja) 2016-04-07
JP2018035191A (ja) 2018-03-08
EP2347770B2 (de) 2019-10-23
DK1704864T3 (da) 2012-09-03
DK2347770T4 (da) 2020-02-03
ATE339225T1 (de) 2006-10-15
ES2385230T3 (es) 2012-07-19
EP2347770B1 (de) 2017-03-08
CA2374964C (en) 2012-05-22
JP2003501486A (ja) 2003-01-14
ES2623017T5 (es) 2020-04-07
DE50013468D1 (de) 2006-10-26
CY1113370T1 (el) 2016-06-22
DE19926154A1 (de) 2000-12-14
EP1704864A2 (de) 2006-09-27
US8846602B2 (en) 2014-09-30
US7387771B1 (en) 2008-06-17
CY1105701T1 (el) 2010-12-22
DK1183050T3 (da) 2007-01-02
US8153581B2 (en) 2012-04-10
SI1704864T1 (sl) 2012-09-28
JP5871483B2 (ja) 2016-03-01
ES2623017T3 (es) 2017-07-10
CA2374964A1 (en) 2000-12-21
JP6290166B2 (ja) 2018-03-07
PT1183050E (pt) 2007-01-31
WO2000076551A2 (de) 2000-12-21
EP2347770A2 (de) 2011-07-27
EP1183050B1 (de) 2006-09-13
AU5970900A (en) 2001-01-02
JP2011173913A (ja) 2011-09-08
PT1704864E (pt) 2012-07-02
JP6573947B2 (ja) 2019-09-11

Similar Documents

Publication Publication Date Title
AU779697B2 (en) Method for producing an injectable medicament preparation
JP5392956B2 (ja) 担体−薬物複合体
US8957016B2 (en) Tumor activated prodrugs
US7803903B2 (en) Protein-binding doxorubicin peptide derivatives
US20100041615A1 (en) Protein-binding methotrexate derivatives, and medicaments containing the same
JP2003534387A (ja) 腫瘍活性化プロドラッグ化合物、並びにこれらの製造方法及び使用方法
US20120094892A1 (en) Prodrugs
US20040033957A1 (en) FAP-activated anti-tumor prodrugs
HK1160382A (en) Process for producing an injectable pharmaceutical preparation

Legal Events

Date Code Title Description
MK14 Patent ceased section 143(a) (annual fees not paid) or expired